Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study
BACKGROUND: The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We performed an observational study on the short-term effects of ELX/TEZ/IVA on glucose tolerance. METHODS: Sixteen adolescents with CF...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070552/ https://www.ncbi.nlm.nih.gov/pubmed/35529332 http://dx.doi.org/10.3389/fped.2022.852551 |
_version_ | 1784700665064325120 |
---|---|
author | Korten, Insa Kieninger, Elisabeth Krueger, Linn Bullo, Marina Flück, Christa E. Latzin, Philipp Casaulta, Carmen Boettcher, Claudia |
author_facet | Korten, Insa Kieninger, Elisabeth Krueger, Linn Bullo, Marina Flück, Christa E. Latzin, Philipp Casaulta, Carmen Boettcher, Claudia |
author_sort | Korten, Insa |
collection | PubMed |
description | BACKGROUND: The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We performed an observational study on the short-term effects of ELX/TEZ/IVA on glucose tolerance. METHODS: Sixteen adolescents with CF performed oral glucose tolerance tests (OGTT) before and 4–6 weeks after initiating ELX/TEZ/IVA therapy. A continuous glucose monitoring (CGM) system was used 3 days before until 7 days after starting ELX/TEZ/IVA treatment. RESULTS: OGTT categories improved after initiating ELX/TEZ/IVA therapy (p = 0.02). Glucose levels of OGTT improved at 60, 90, and 120 min (p < 0.05), whereas fasting glucose and CGM measures did not change. CONCLUSION: Shortly after initiating ELX/TEZ/IVA therapy, glucose tolerance measured by OGTT improved in people with CF. This pilot study indicates that ELX/TEZ/IVA treatment has beneficial effects on the endocrine pancreatic function and might prevent or at least postpone future CFRD. |
format | Online Article Text |
id | pubmed-9070552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90705522022-05-05 Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study Korten, Insa Kieninger, Elisabeth Krueger, Linn Bullo, Marina Flück, Christa E. Latzin, Philipp Casaulta, Carmen Boettcher, Claudia Front Pediatr Pediatrics BACKGROUND: The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We performed an observational study on the short-term effects of ELX/TEZ/IVA on glucose tolerance. METHODS: Sixteen adolescents with CF performed oral glucose tolerance tests (OGTT) before and 4–6 weeks after initiating ELX/TEZ/IVA therapy. A continuous glucose monitoring (CGM) system was used 3 days before until 7 days after starting ELX/TEZ/IVA treatment. RESULTS: OGTT categories improved after initiating ELX/TEZ/IVA therapy (p = 0.02). Glucose levels of OGTT improved at 60, 90, and 120 min (p < 0.05), whereas fasting glucose and CGM measures did not change. CONCLUSION: Shortly after initiating ELX/TEZ/IVA therapy, glucose tolerance measured by OGTT improved in people with CF. This pilot study indicates that ELX/TEZ/IVA treatment has beneficial effects on the endocrine pancreatic function and might prevent or at least postpone future CFRD. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9070552/ /pubmed/35529332 http://dx.doi.org/10.3389/fped.2022.852551 Text en Copyright © 2022 Korten, Kieninger, Krueger, Bullo, Flück, Latzin, Casaulta and Boettcher. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Korten, Insa Kieninger, Elisabeth Krueger, Linn Bullo, Marina Flück, Christa E. Latzin, Philipp Casaulta, Carmen Boettcher, Claudia Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study |
title | Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study |
title_full | Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study |
title_fullStr | Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study |
title_full_unstemmed | Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study |
title_short | Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study |
title_sort | short-term effects of elexacaftor/tezacaftor/ivacaftor combination on glucose tolerance in young people with cystic fibrosis—an observational pilot study |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070552/ https://www.ncbi.nlm.nih.gov/pubmed/35529332 http://dx.doi.org/10.3389/fped.2022.852551 |
work_keys_str_mv | AT korteninsa shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy AT kieningerelisabeth shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy AT kruegerlinn shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy AT bullomarina shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy AT fluckchristae shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy AT latzinphilipp shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy AT casaultacarmen shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy AT boettcherclaudia shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy |